398 related articles for article (PubMed ID: 24631834)
1. Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents.
Turner JG; Dawson J; Cubitt CL; Baz R; Sullivan DM
Semin Cancer Biol; 2014 Aug; 27():62-73. PubMed ID: 24631834
[TBL] [Abstract][Full Text] [Related]
2. Nuclear export of proteins and drug resistance in cancer.
Turner JG; Dawson J; Sullivan DM
Biochem Pharmacol; 2012 Apr; 83(8):1021-32. PubMed ID: 22209898
[TBL] [Abstract][Full Text] [Related]
3. Nucleo-cytoplasmic transport as a therapeutic target of cancer.
Gravina GL; Senapedis W; McCauley D; Baloglu E; Shacham S; Festuccia C
J Hematol Oncol; 2014 Dec; 7():85. PubMed ID: 25476752
[TBL] [Abstract][Full Text] [Related]
4. Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells.
Etchin J; Sun Q; Kentsis A; Farmer A; Zhang ZC; Sanda T; Mansour MR; Barcelo C; McCauley D; Kauffman M; Shacham S; Christie AL; Kung AL; Rodig SJ; Chook YM; Look AT
Leukemia; 2013 Jan; 27(1):66-74. PubMed ID: 22847027
[TBL] [Abstract][Full Text] [Related]
5. Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein.
Ishizawa J; Kojima K; Hail N; Tabe Y; Andreeff M
Pharmacol Ther; 2015 Sep; 153():25-35. PubMed ID: 26048327
[TBL] [Abstract][Full Text] [Related]
6. Novel reversible selective inhibitor of nuclear export shows that CRM1 is a target in colorectal cancer cells.
Niu M; Chong Y; Han Y; Liu X
Cancer Biol Ther; 2015; 16(7):1110-8. PubMed ID: 25996664
[TBL] [Abstract][Full Text] [Related]
7. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition.
Turner JG; Marchion DC; Dawson JL; Emmons MF; Hazlehurst LA; Washausen P; Sullivan DM
Cancer Res; 2009 Sep; 69(17):6899-905. PubMed ID: 19690141
[TBL] [Abstract][Full Text] [Related]
8. Atomic basis of CRM1-cargo recognition, release and inhibition.
Fung HY; Chook YM
Semin Cancer Biol; 2014 Aug; 27():52-61. PubMed ID: 24631835
[TBL] [Abstract][Full Text] [Related]
9. Structure-Guided Design of the First Noncovalent Small-Molecule Inhibitor of CRM1.
Lei Y; An Q; Shen XF; Sui M; Li C; Jia D; Luo Y; Sun Q
J Med Chem; 2021 May; 64(10):6596-6607. PubMed ID: 33974430
[TBL] [Abstract][Full Text] [Related]
10. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity.
Sakakibara K; Saito N; Sato T; Suzuki A; Hasegawa Y; Friedman JM; Kufe DW; Vonhoff DD; Iwami T; Kawabe T
Blood; 2011 Oct; 118(14):3922-31. PubMed ID: 21841164
[TBL] [Abstract][Full Text] [Related]
11. Nuclear Export as a Novel Therapeutic Target: The CRM1 Connection.
Lu C; Figueroa JA; Liu Z; Konala V; Aulakh A; Verma R; Cobos E; Chiriva-Internati M; Gao W
Curr Cancer Drug Targets; 2015; 15(7):575-92. PubMed ID: 26324128
[TBL] [Abstract][Full Text] [Related]
12. Leptomycin B alters the subcellular distribution of CRM1 (Exportin 1).
Rahmani K; Dean DA
Biochem Biophys Res Commun; 2017 Jun; 488(2):253-258. PubMed ID: 28412356
[TBL] [Abstract][Full Text] [Related]
13. Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1.
Sun Q; Carrasco YP; Hu Y; Guo X; Mirzaei H; Macmillan J; Chook YM
Proc Natl Acad Sci U S A; 2013 Jan; 110(4):1303-8. PubMed ID: 23297231
[TBL] [Abstract][Full Text] [Related]
14. Using a Simple Cellular Assay to Map NES Motifs in Cancer-Related Proteins, Gain Insight into CRM1-Mediated NES Export, and Search for NES-Harboring Micropeptides.
Sendino M; Omaetxebarria MJ; Prieto G; Rodriguez JA
Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32882917
[TBL] [Abstract][Full Text] [Related]
15. CRM1-mediated nuclear export of proteins and drug resistance in cancer.
Turner JG; Sullivan DM
Curr Med Chem; 2008; 15(26):2648-55. PubMed ID: 18991627
[TBL] [Abstract][Full Text] [Related]
16. A cellular reporter to evaluate CRM1 nuclear export activity: functional analysis of the cancer-related mutant E571K.
García-Santisteban I; Arregi I; Alonso-Mariño M; Urbaneja MA; Garcia-Vallejo JJ; Bañuelos S; Rodríguez JA
Cell Mol Life Sci; 2016 Dec; 73(24):4685-4699. PubMed ID: 27312238
[TBL] [Abstract][Full Text] [Related]
17. Engineering chromosome region maintenance 1 fragments that bind to nuclear export signals.
Lei Y; An Q; Zhang Y; Luo P; Luo Y; Shen X; Jia D; Sun Q
Protein Sci; 2020 Jun; 29(6):1366-1372. PubMed ID: 31495993
[TBL] [Abstract][Full Text] [Related]
18. Structural basis for leucine-rich nuclear export signal recognition by CRM1.
Dong X; Biswas A; Süel KE; Jackson LK; Martinez R; Gu H; Chook YM
Nature; 2009 Apr; 458(7242):1136-41. PubMed ID: 19339969
[TBL] [Abstract][Full Text] [Related]
19. CRM1 Promotes Capsid Disassembly and Nuclear Envelope Translocation of Adenovirus Independently of Its Export Function.
Lagadec F; Carlon-Andres I; Ragues J; Port S; Wodrich H; Kehlenbach RH
J Virol; 2022 Feb; 96(3):e0127321. PubMed ID: 34757845
[TBL] [Abstract][Full Text] [Related]
20. Ratjadone and leptomycin B block CRM1-dependent nuclear export by identical mechanisms.
Meissner T; Krause E; Vinkemeier U
FEBS Lett; 2004 Oct; 576(1-2):27-30. PubMed ID: 15474004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]